RFP | July 24, 2014
U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute announces the availability of funding for implementation of the Bioreactors for Reparative Medicine - Small Business Innovation Research (SBIR) Direct Phase II (R44) Grant. The purpose of this grant is to encourage small businesses to develop sophisticated and complex biomimetic culture systems which address the unique physiological dynamics of heart, lung, and blood tissues. Contractors should refer to Section VII, Agency Contacts, in the RFP for information regarding each Institute's grants management contact for this program . . .